HR Execs on the Move

Oxford Health Plans

www.oxhp.com

 
Oxford Health Plans, Inc. is a healthcare company providing health benefit plans primarily in New York, New Jersey and Connecticut. Its product line includes its health maintenance organization plans, exclusive provider organization plans,
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Dental Masters Laboratory

Dental Masters Laboratory is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Instrumed International

Instrumed International is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St. John's

St. Johns Lutheran Community is a senior living community in Albert Lea, MN that provides short term care, skilled nursing care, independent living, assisted living, and memory care homes.

T1D Exchange

T1D Exchange, a nonprofit organization, is a dynamic, multi-purpose, real-world patient data platform designed to accelerate all aspects of drug and device development. T1D Exchange has established a unique model to speed better treatments, therapies and research for type 1 diabetes (T1D). The Exchange consists of an integrated Clinic Network of 65+ clinics across the U.S., a Clinic Registry of 26,000 well-characterized patients, a Biorepository, and Glu, an online community with mobile capabilities for people touched by type 1 diabetes. The T1D Exchange fosters faster and more fluid information transfer and sharing among diabetes patients, physicians, researchers, and pharma, medical device, education, and outreach organizations.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.